Pyrimidin-4-yl-3, 4-dihydro-2h-pyrrolo [1,2a] pyrazin-1-one compounds

Abstract

The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein Z is NR, NHCO, NHSO, NHCH, CH, CHCH, or CH═CH; X is a hydrocarbyl group optionally substituted by one or more Rgroups; Rand Rare each independently II or alkyl; R-Rare each independently II or (CII)R, where m is O, 1, 2, or 3; each Ris independently (CH)R, where each Ris independently selected from O(CH)R, R, COR, COOR, CN, CONRR, NRR, NRCOR, SR, SOR, SOR, NRSOR, SOOR, SONRR, halogen, CF, and NO, and wherein each a is 0, 1, 2, or 3 and b is 0, 1, 2, or 3; Rand Rare each independently H or (CH)R, where n is 0, 1, 2, or 3; and each Ris independently selected from alkyl, cycloalkyl, heteroaryl, aralkyl, aryl and heterocycloalkyl, each of which may be optionally substituted by one or more substituents selected from halogen, OH, CN, COO-alkyl, aralkyl, SO-alkyl, SO-aryl, COOH, CO-alkyl, CO-aryl, NH, NH-alkyl, N(alkyl), CF, alkyl and alkoxy, wherein said alkyl and alkoxy groups may be further substituted by one or more OH groups. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula I, and the use of compounds of formula (I) in the preparation of a medicament for treating a variety of disorders, including proliferative disorders, viral disorders, stroke, etc.